IOVA

Iovance Biotherapeutics Inc

Feb 27 • 04:00PM ET

3.86

+0.07 1.85 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FATE TVRD PRTA CRSP EDIT SGMO QURE ADAP NTLA

| Held by: XBI VTI IWM VB IWN IBB VXF VBR SCHA KOMP

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	14.76%	Shs Outstand	411.94M	Perf Week	34.49%
Market Cap	1.59B	Forward P/E	-	EPS next Y	-0.22	Insider Trans	0.00%	Shs Float	351.15M	Perf Month	40.36%
Enterprise Value	1.34B	PEG	-	EPS next Q	-0.14	Inst Own	57.09%	Short Float	37.40%	Perf Quarter	55.65%
Income	-390.98M	P/S	6.04	EPS this Y	54.15%	Inst Trans	15.17%	Short Ratio	10.19	Perf Half Y	59.50%
Sales	263.44M	P/B	2.28	EPS next Y	56.81%	ROA	-42.88%	Short Interest	131.33M	Perf YTD	41.39%
Book/sh	1.70	P/C	5.35	EPS next 5Y	-	ROE	-55.50%	52W High	5.64 -31.56%	Perf Year	-26.62%
Cash/sh	0.72	P/FCF	-	EPS past 3/5Y	23.93% 10.23%	ROIC	-52.62%	52W Low	1.64 135.58%	Perf 3Y	-46.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	17.09%	Volatility	11.94% 8.13%	Perf 5Y	-89.65%
Dividend TTM	-	EV/Sales	5.10	EPS Y/Y TTM	13.67%	Oper. Margin	-151.18%	ATR (14)	0.27	Perf 10Y	-27.72%
Dividend Ex-Date	-	Quick Ratio	2.83	Sales Y/Y TTM	60.57%	Profit Margin	-148.41%	RSI (14)	78.94	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	31.43%	SMA20	34.89%	Beta	0.71	Target Price	9.56
Payout	-	Debt/Eq	0.07	Sales Q/Q	17.66%	SMA50	42.81%	Rel Volume	1.47	Prev Close	3.79
Employees	975	LT Debt/Eq	0.06	Earnings	Feb 24 BMO	SMA200	65.16%	Avg Volume	12.89M	Price	3.86
IPO	Sep 01, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.92% 7.44%	Trades		Volume	18,956,816	Change	1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform	$5
Jul-15-25	Downgrade	Goldman	Neutral → Sell	$1
May-16-25	Downgrade	UBS	Buy → Neutral	$2
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy	$17
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral	$19 → $10
Nov-20-23	Initiated	Goldman	Buy	$12
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Feb-26-26 02:27PM	Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success (Insider Monkey)
09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Feb-25-26 01:33PM	Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why (24/7 Wall St.)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
04:32PM	Loading…
Feb-24-26 04:32PM	Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +30.80%
04:01PM	Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:14PM	Iovance Biotherapeutics Explodes Over 20% - Early Trial Data Sparks Investor Frenzy (Benzinga)
12:49PM	Iovance Biotherapeutics Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
09:02AM	IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? (Zacks)
07:26AM	Iovance Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates (GlobeNewswire)
07:00AM	Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas (GlobeNewswire)
Feb-23-26 09:58AM	Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive (Insider Monkey)
05:15PM	Loading…
Feb-20-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 09:58AM	Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? (Insider Monkey)
Feb-17-26 08:41PM	Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data (Insider Monkey)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 (GlobeNewswire)
Feb-06-26 11:02AM	Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure (Insider Monkey) +7.20%
Feb-05-26 05:15PM	Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma (GlobeNewswire)
Jan-16-26 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.31%
Jan-15-26 02:33PM	Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory (Insider Monkey) -6.72%
Dec-31-25 11:13AM	Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-19-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.10%
Dec-07-25 09:45AM	2 Stocks That Could Soar by 52% and 282%, According to Wall Street (Motley Fool)
Nov-21-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +11.61%
Nov-11-25 06:45AM	Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? (Motley Fool) +11.81%
01:45PM	Loading…
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
08:45AM	2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street (Motley Fool)
Nov-06-25 09:15AM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +27.62%
08:19AM	Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results (GlobeNewswire)
Nov-05-25 05:20PM	Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates (Zacks)
Nov-04-25 06:00PM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -6.67%
Nov-03-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline (Zacks)
07:00AM	Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire)
Oct-23-25 04:05PM	Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 (GlobeNewswire)
Oct-17-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.42%
06:17AM	Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health (Motley Fool)
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire) +5.66%
Oct-13-25 05:53AM	Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? (Motley Fool)
Sep-20-25 02:43AM	Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts (Insider Monkey)
Sep-19-25 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.82%
10:05AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Sep-17-25 08:30AM	Advancing Cancer Research Brings New Hope for Patients Worldwide (PR Newswire)
Sep-08-25 12:30AM	H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News (Insider Monkey)
Aug-29-25 08:30AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-27-25 04:28PM	If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today (Motley Fool) -7.85%
Aug-26-25 09:17AM	IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
Aug-25-25 05:15PM	Why Iovance Biotherapeutics Stock Got Mashed on Monday (Motley Fool) -5.95%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:48AM	Artisan Small Cap Fund Exited Its Stake in Iovance Biotherapeutics (IOVA) Due to Operational Challenges (Insider Monkey)
Aug-24-25 09:30AM	1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street (Motley Fool)
Aug-22-25 11:45PM	Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada (Insider Monkey) +5.91% -5.95%
05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-19-25 03:16PM	Why Iovance Biotherapeutics Stock Was Climbing Today (Motley Fool)
Aug-18-25 04:15PM	Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma (GlobeNewswire)
Aug-17-25 11:41PM	Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth (Insider Monkey)
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +9.87%
Aug-12-25 05:31PM	Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications \| DelveInsight (PR Newswire) +13.20%
Aug-09-25 04:21AM	3 Stocks That Could Turn $1,000 Into $5,000 by 2030 (Motley Fool)
Aug-08-25 07:31PM	Why Iovance Biotherapeutics Stock Plummeted Today (Motley Fool) -20.08% -6.64%
12:47PM	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 (GlobeNewswire)
06:02AM	Iovance cuts staff amid slow sales start for TIL cell therapy (BioPharma Dive)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.18%
Aug-05-25 06:05PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-01-25 06:46AM	Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges (Insider Monkey)
Jul-30-25 04:46AM	Is Iovance Biotherapeutics Stock Due for a Big Rally? (Motley Fool) -8.56%
Jul-29-25 03:29AM	This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? (Motley Fool)
Jul-24-25 04:05PM	Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 (GlobeNewswire) -17.13%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Jul-23-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +26.84%
Jul-21-25 08:30AM	This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside (Motley Fool) +11.66%
Jul-18-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 07:30AM	Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer (GlobeNewswire)
Jul-14-25 07:30AM	Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi in Patients with Advanced Melanoma (GlobeNewswire) +7.49%
Jul-10-25 04:01PM	Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy (GlobeNewswire)
Jul-06-25 06:47AM	Is This Beaten-Down Stock a Millionaire Maker? (Motley Fool)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 06:57PM	Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week (Motley Fool)
12:00PM	Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA) (Newsfile)
Jun-24-25 01:36PM	Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure - Hagens Berman (Newsfile)
09:00AM	Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA (PR Newswire)
Jun-23-25 04:05PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.57%
Jun-20-25 11:56AM	Gene Therapy Stocks Fall as FDA Pushes Out Another Top Regulator (Barrons.com)
11:56AM	Gene Therapy Stocks Fall Amid More Turmoil at FDA (Barrons.com)
Jun-19-25 01:03PM	Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure- Hagens Berman (Newsfile)
Jun-16-25 02:00PM	Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman (Newsfile) -7.14%
Jun-13-25 05:45AM	Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVA (PR Newswire)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
Jun-10-25 06:35PM	Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman (Newsfile) +7.69% -5.88%
08:45AM	Iovance Biotherapeutics to Present at Upcoming Conference (GlobeNewswire)
Jun-06-25 05:45AM	Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA (PR Newswire) +13.89%

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kirby Daniel Gordon	Chief Commercial Officer	Feb 24 '26	Option Exercise	0.00	120,000	0	173,546	Feb 26 05:00 PM
Kirby Daniel Gordon	Chief Commercial Officer	Feb 10 '26	Option Exercise	0.00	39,996	0	69,996	Feb 12 05:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 02 '25	Option Exercise	0.00	3,906	0	113,640	Dec 03 05:04 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 01 '25	Option Exercise	0.00	8,789	0	114,198	Dec 03 05:04 PM
BILINSKY IGOR	Chief Operating Officer	Dec 02 '25	Option Exercise	0.00	3,516	0	107,530	Dec 03 05:02 PM
BILINSKY IGOR	Chief Operating Officer	Dec 01 '25	Option Exercise	0.00	8,789	0	108,478	Dec 03 05:02 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 02 '25	Option Exercise	0.00	10,417	0	468,948	Dec 03 05:01 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 01 '25	Option Exercise	0.00	41,669	0	476,232	Dec 03 05:01 PM
Puri Raj K.	Chief Regulatory Officer	Dec 01 '25	Option Exercise	0.00	5,469	0	218,326	Dec 03 05:00 PM
Vogt Frederick G	Interim CEO & General Counsel	Sep 02 '25	Option Exercise	0.00	52,086	0	456,690	Sep 04 06:35 PM
Puri Raj K.	Chief Regulatory Officer	Sep 02 '25	Option Exercise	0.00	5,470	0	215,324	Sep 04 06:30 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Sep 02 '25	Option Exercise	0.00	12,697	0	111,857	Sep 04 06:30 PM
BILINSKY IGOR	Chief Operating Officer	Sep 02 '25	Option Exercise	0.00	12,306	0	105,939	Sep 04 06:30 PM
Kirby Daniel Gordon	Chief Commercial Officer	Jun 05 '25	Buy	1.84	30,000	55,200	30,000	Jun 06 04:05 PM
Puri Raj K.	Chief Regulatory Officer	Jun 02 '25	Option Exercise	0.00	5,469	0	212,321	Jun 04 04:51 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 02 '25	Option Exercise	0.00	52,085	0	426,731	Jun 04 04:50 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 02 '25	Option Exercise	0.00	12,695	0	105,608	Jun 04 04:49 PM
BILINSKY IGOR	Chief Operating Officer	Jun 02 '25	Option Exercise	0.00	12,305	0	99,883	Jun 04 04:47 PM
Bellemin Jean-Marc	Chief Financial Officer	Jun 02 '25	Option Exercise	0.00	8,789	0	64,993	Jun 04 04:46 PM
Puri Raj K.	Chief Regulatory Officer	May 23 '25	Buy	1.74	5,600	9,743	206,852	May 27 04:06 PM
Vogt Frederick G	Interim CEO & General Counsel	May 14 '25	Buy	1.69	25,000	42,250	374,646	May 16 04:05 PM
Puri Raj K.	Chief Regulatory Officer	Mar 14 '25	Option Exercise	0.00	8,334	0	203,761	Mar 18 08:30 PM
Bellemin Jean-Marc	Chief Financial Officer	Mar 03 '25	Option Exercise	0.00	58,590	0	87,938	Mar 05 08:33 PM
BILINSKY IGOR	Chief Operating Officer	Mar 03 '25	Option Exercise	0.00	62,106	0	120,880	Mar 05 08:32 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 03 '25	Option Exercise	0.00	223,943	0	445,059	Mar 05 08:32 PM
Puri Raj K.	Chief Regulatory Officer	Mar 03 '25	Option Exercise	0.00	59,999	0	215,411	Mar 05 08:31 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 03 '25	Option Exercise	0.00	62,497	0	126,383	Mar 05 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA

Iovance Biotherapeutics Inc

Upgrade your FINVIZ experience